Standard BioTools Reports First Quarter 2025 Financial Results
- 45% reduction in operating loss year-over-year
- 29% improvement in adjusted EBITDA compared to Q1 2024
- Strong balance sheet with $261M cash and no material debt
- 24% year-over-year growth in instruments revenue
- Operationalized additional $10M in annual cost reductions, totaling $90M since merger
- 38% decrease in operating expenses to $52.7M
- 10% year-over-year decline in total revenue to $40.8M
- 16% decrease in consumables revenue
- 16% decline in services revenue
- Gross margin decreased to 48.4% from 53.1% year-over-year
- Net loss of $26.0M despite improvements
- Anticipated decline in Americas academic revenue due to NIH funding pressures
Insights
Despite revenue decline, Standard BioTools shows progress in cost reduction and EBITDA improvement while maintaining strong cash position during industry challenges.
Standard BioTools' Q1 2025 results reflect a company in transition, balancing revenue challenges with impressive operational efficiency gains. The 10% year-over-year revenue decline to
The revenue breakdown reveals important dynamics: while instruments grew
The company's operational discipline is evident in their
Management's maintained revenue guidance of
Standard BioTools strategically positions in proteomics with SomaScan tech and Illumina partnership while navigating revenue challenges through operational efficiency.
Standard BioTools is making a calculated strategic pivot toward proteomics technologies while managing through industrywide funding pressures. The
Most notable is management's emphasis on their SomaScan and SOMAmer technology. These aptamer-based proteomics approaches offer distinct advantages over traditional antibody methods, particularly in throughput, reproducibility, and dynamic range. The mention of validation at AACR (American Association for Cancer Research) suggests growing adoption in oncology applications, where multi-protein signatures are increasingly valuable for both diagnostic and therapeutic development.
The upcoming NGS-based proteomics product launch with Illumina represents a potentially transformative development. By integrating proteomics with Illumina's dominant sequencing infrastructure, Standard BioTools could significantly expand their addressable market by lowering barriers to proteomics adoption. This approach effectively piggybacks on existing sequencing workflows rather than requiring completely separate instrumentation.
However, the
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended March 31, 2025.
Recent Highlights:
- First quarter 2025 revenue of
$40.8 million 45% reduction in operating loss and29% improvement in adjusted EBITDA year-over-year- Operationalized
$10 million more in annual run rate cost reductions, totaling$90 million since merger - Strong balance sheet with
$261 million in cash & cash equivalents and no material debt as of March 31, 2025
“Standard BioTools delivered a solid first quarter in line with our expectations, reflecting focused execution in a challenging Life Sciences macro backdrop,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "We remain grounded and disciplined, driving a
Dr. Egholm added, "On a product level, I am particularly excited by our strategic foothold in proteomics and the momentum building for SomaScan and SOMAmers. The advantages and performance over legacy antibody-based approaches is now well-documented, most recently at the AACR Annual Meeting and through a growing list of publications. As population-based proteomics studies continue to favor our technology, the upcoming launch of our Illumina partnered NGS-based product will only further expand access. Together we expect this momentum to accelerate as we help usher in an exciting new era of proteomic discovery.
Financial Results Table:
| Three Months Ended March 31, | |||||||
| (Unaudited, in millions, except percentages) | 2025 | 2024 | |||||
| Revenue | $ | 40.8 | $ | 45.5 | |||
| Gross margin | |||||||
| Non-GAAP gross margin | |||||||
| Operating expenses | $ | 52.7 | $ | 84.4 | |||
| Non-GAAP operating expenses | $ | 38.6 | $ | 49.3 | |||
| Operating loss | $ | (33.0 | ) | $ | (60.2 | ) | |
| Net loss | $ | (26.0 | ) | $ | (32.2 | ) | |
| Adjusted EBITDA | $ | (16.9 | ) | $ | (23.7 | ) | |
| Cash, cash equivalents, restricted cash, and short-term investments | $ | 260.70 | $ | 463.6 | |||
First Quarter 2025 Financial Results
- Revenue was
$40.8 million in the first quarter of 2025, down10% year-over-year:- Consumables revenue was
$14.5 million in the first quarter of 2025, down16% year-over-year. Consumables revenue declined due to lower volume. - Instruments revenue was
$7.8 million in the first quarter of 2025, up24% year-over-year. Instrument revenue was driven by strong growth in our Hyperion XTi spatial proteomics platform. - Services revenue, which includes both Lab Services and Field Services, was
$17.6 million in the first quarter of 2025, down16% year-over-year. Lab Services revenue was down19% due to a tough comparable to prior-year levels that benefited from elevated backlog as well as project timing.
- Consumables revenue was
- Gross margins in the first quarter of 2025 were
48.4% , versus53.1% in the first quarter of 2024; and non-GAAP gross margins, which exclude depreciation, amortization, and stock-based compensation, were53.2% in the first quarter of 2025 versus56.2% in the first quarter of 2024. Gross margins were impacted by lower volume, price realization and product mix, partially offset by incremental improvements from SBS. - Operating expenses in the first quarter of 2025 were
$52.7 million , a decrease of$31.7 million , or down38% , compared to the first quarter of 2024; and non-GAAP operating expenses, which exclude merger-related costs, stock-based compensation, and restructuring charges, were$38.6 million in the first quarter of 2025, a decrease of$10.7 million , or down22% , compared to the first quarter of 2024. The decrease in operating expenses is a result of the realization of merger cost synergies and continued productivity gains from SBS. - Net loss for the first quarter of 2025 was
$26.0 million , compared to a net loss of$32.2 million in the first quarter of 2024, representing an improvement of$6.2 million or19% , while adjusted EBITDA for the first quarter of 2025 was a loss of$16.9 million , versus an adjusted EBITDA loss of$23.7 million in the first quarter of 2024, an improvement of$6.8 million , or29% .
Full Year 2025 Revenue Outlook
For fiscal year 2025, the Company continues to expect revenue in the range of
Conference Call Information
Standard BioTools will host a conference call and webcast on May 6th, 2025, at 4:30 p.m. ET to discuss the first quarter 2025 financial results. Live audio of the webcast will be available online along with an archived version of the webcast under the Events & Presentations page of the Company’s website.
Individuals interested in listening to the conference call may do so by dialing:
US domestic callers: (888) 346-3970
Outside US callers: (412) 902-4297
Use of Non-GAAP Financial Information
Standard BioTools has presented certain financial information in accordance with U.S. GAAP and on a non-GAAP basis. The non-GAAP financial measures included in this press release are non-GAAP gross margin, non-GAAP gross profit, non-GAAP operating expenses, and adjusted EBITDA. Management uses these non-GAAP financial measures, in addition to GAAP financial measures, as a measure of operating performance because the non-GAAP financial measures do not include the impact of items that management does not consider indicative of the Company’s core operating performance. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the Company’s core operating results. Management uses non-GAAP measures to compare the Company’s performance relative to forecasts and strategic plans and to benchmark the Company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the Company’s operating results as reported under U.S. GAAP. Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding future financial and business performance, including with respect to future revenue; operational and strategic plans; deployment of capital; market and growth opportunity and potential; and the potential to realize the expected benefits and synergies of prior and potential future acquisitions, including the potential for such transactions to drive long-term profitable growth. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, risks that the anticipated benefits and synergies of prior and potential future acquisitions and the integration of any such businesses, including the potential for such transactions to drive long-term profitable growth, may not be fully realized or may take longer to realize than expected; risks that the Company may not realize expected cost savings from such transactions; possible integration, restructuring and transition-related disruption resulting from such transactions, including through the loss of customers, suppliers, and employees and adverse impacts on the Company’s development activities and results of operation; integration and restructuring activities, including customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause the Company to use cash more quickly than it expects or change or curtail some of the Company’s plans, or both; risks that the Company’s expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in the Company’s business or external market conditions; anticipated NIH funding pressures; the expected effect from U.S. export controls and the expected impact from tariffs; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, the Company’s products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to the Company’s research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the “Risk Factors” section of the Company’s annual report on Form 10-K filed with the SEC on March 11, 2025, and in the Company’s other filings with the SEC. These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements except as may be required by law.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2025 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Investor Contact:
ir@standardbio.com
| STANDARD BIOTOOLS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Revenue: | ||||||||
| Product revenue | $ | 22,232 | $ | 23,592 | ||||
| Services revenue | 17,607 | 21,027 | ||||||
| Collaboration and other revenue | 956 | 921 | ||||||
| Total revenue | 40,795 | 45,540 | ||||||
| Cost of revenue: | ||||||||
| Cost of product revenue | 10,730 | 12,781 | ||||||
| Cost of services revenue | 10,302 | 8,509 | ||||||
| Cost of collaboration and other revenue | 22 | 62 | ||||||
| Total cost of revenue | 21,054 | 21,352 | ||||||
| Gross profit | 19,741 | 24,188 | ||||||
| Operating expenses: | ||||||||
| Research and development | 11,328 | 15,980 | ||||||
| Selling, general and administrative | 38,707 | 46,943 | ||||||
| Restructuring and related charges | 1,552 | 4,284 | ||||||
| Transaction and integration expenses | 1,124 | 17,163 | ||||||
| Total operating expenses | 52,711 | 84,370 | ||||||
| Loss from operations | (32,970 | ) | (60,182 | ) | ||||
| Bargain purchase gain | — | 25,213 | ||||||
| Interest income | 2,916 | 6,207 | ||||||
| Interest expense | (2 | ) | (1,033 | ) | ||||
| Other income (expense), net | 3,872 | (2,234 | ) | |||||
| Loss before income taxes | (26,184 | ) | (32,029 | ) | ||||
| Income tax benefit (expense) | 151 | (128 | ) | |||||
| Net loss | $ | (26,033 | ) | $ | (32,157 | ) | ||
| Induced conversion of redeemable preferred stock | — | (46,014 | ) | |||||
| Net loss attributable to common stockholders | $ | (26,033 | ) | $ | (78,171 | ) | ||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.07 | ) | $ | (0.27 | ) | ||
| Shares used in computing net loss per share attributable to common stockholders, basic and diluted | 378,228 | 294,125 | ||||||
| STANDARD BIOTOOLS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) | ||||||||
| March 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 150,880 | $ | 166,728 | ||||
| Short-term investments | 107,182 | 126,146 | ||||||
| Accounts receivable, net | 35,480 | 33,608 | ||||||
| Inventory | 42,125 | 40,737 | ||||||
| Prepaid expenses and other current assets | 8,352 | 8,661 | ||||||
| Total current assets | 344,019 | 375,880 | ||||||
| Inventory, non-current | 18,281 | 18,528 | ||||||
| Property and equipment, net | 43,593 | 42,556 | ||||||
| Operating lease right-of-use asset, net | 27,422 | 28,828 | ||||||
| Other non-current assets | 6,506 | 6,301 | ||||||
| Acquired intangible assets, net | 28,057 | 28,954 | ||||||
| Goodwill | 111,719 | 111,297 | ||||||
| Total assets | $ | 579,597 | $ | 612,344 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 11,778 | $ | 12,282 | ||||
| Accrued liabilities | 21,972 | 30,739 | ||||||
| Operating lease liabilities, current | 6,334 | 6,228 | ||||||
| Deferred revenue, current | 12,763 | 13,118 | ||||||
| Deferred grant income, current | 3,389 | 3,527 | ||||||
| Total current liabilities | 56,236 | 65,894 | ||||||
| Convertible notes, non-current | 299 | 299 | ||||||
| Deferred tax liability | 1,031 | 1,081 | ||||||
| Operating lease liabilities, non-current | 24,897 | 26,469 | ||||||
| Deferred revenue, non-current | 32,548 | 32,674 | ||||||
| Deferred grant income, non-current | 6,501 | 7,243 | ||||||
| Other non-current liabilities | 3,490 | 6,962 | ||||||
| Total liabilities | 125,002 | 140,622 | ||||||
| Total stockholders’ equity | 454,595 | 471,722 | ||||||
| Total liabilities and stockholders’ equity | $ | 579,597 | $ | 612,344 | ||||
| STANDARD BIOTOOLS INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Operating activities | ||||||||
| Net loss | $ | (26,033 | ) | $ | (32,157 | ) | ||
| Bargain purchase gain | — | (25,213 | ) | |||||
| Stock-based compensation expense | 9,009 | 11,611 | ||||||
| Amortization of acquired intangible assets | 898 | 2,106 | ||||||
| Depreciation and amortization | 3,273 | 3,088 | ||||||
| Accretion of discount on short-term investments, net | (841 | ) | (2,660 | ) | ||||
| Non-cash lease expense | 1,438 | 1,446 | ||||||
| Provision for excess and obsolete inventory | 815 | 655 | ||||||
| Change in fair value of warrants | (232 | ) | 853 | |||||
| Change in fair value of contingent consideration | (3,400 | ) | — | |||||
| Other non-cash items | 385 | 293 | ||||||
| Changes in assets and liabilities, net | (15,595 | ) | (22,498 | ) | ||||
| Net cash used in operating activities | (30,283 | ) | (62,476 | ) | ||||
| Investing activities | ||||||||
| Cash and restricted cash acquired in merger | — | 280,033 | ||||||
| Purchases of short-term investments | (32,321 | ) | (73,177 | ) | ||||
| Proceeds from sales and maturities of investments | 52,000 | 112,000 | ||||||
| Purchases of property and equipment | (5,054 | ) | (781 | ) | ||||
| Net cash provided by investing activities | 14,625 | 318,075 | ||||||
| Financing activities | ||||||||
| Repayment of term loan and convertible notes | — | (8,192 | ) | |||||
| Payment of term loan fee | — | (545 | ) | |||||
| Repurchase of common stock | — | (11,051 | ) | |||||
| Payments for taxes related to net share settlement of equity awards and other | (46 | ) | (17 | ) | ||||
| Proceeds from exercise of stock options | — | 72 | ||||||
| Net cash used in financing activities | (46 | ) | (19,733 | ) | ||||
| Effect of foreign exchange rate fluctuations on cash and cash equivalents | 357 | (21 | ) | |||||
| Net increase in cash, cash equivalents and restricted cash | (15,347 | ) | 235,845 | |||||
| Cash, cash equivalents and restricted cash at beginning of period | 168,818 | 52,499 | ||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 153,471 | $ | 288,344 | ||||
| Cash, cash equivalents, and restricted cash consists of: | ||||||||
| Cash and cash equivalents | $ | 150,880 | $ | 287,057 | ||||
| Restricted cash | 2,591 | 1,287 | ||||||
| Total cash, cash equivalents and restricted cash | $ | 153,471 | $ | 288,344 | ||||
| STANDARD BIOTOOLS INC. REVENUE (In thousands) (Unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Product revenue: | ||||||||
| Instruments | $ | 7,778 | $ | 6,285 | ||||
| Consumables | 14,454 | 17,307 | ||||||
| Total product revenue | 22,232 | 23,592 | ||||||
| Service revenue: | ||||||||
| Lab services | 12,106 | 14,862 | ||||||
| Field services | 5,501 | 6,165 | ||||||
| Total service revenue | 17,607 | 21,027 | ||||||
| Product and service revenue | 39,839 | 44,619 | ||||||
| Collaboration and other revenue | 956 | 921 | ||||||
| Total revenue | $ | 40,795 | $ | 45,540 | ||||
| STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (In thousands) (Unaudited) | ||||||||
| ITEMIZED RECONCILIATION OF GROSS PROFIT TO NON-GAAP GROSS PROFIT AND MARGIN PERCENTAGE | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Gross profit | $ | 19,741 | $ | 24,188 | ||||
| Amortization of acquired intangible assets | 717 | 1,956 | ||||||
| Depreciation and amortization | 736 | 1,024 | ||||||
| Stock-based compensation expense | 495 | 239 | ||||||
| Loss on disposal of property and equipment | 32 | — | ||||||
| Cost of sales adjustment | — | (1,812 | ) | |||||
| Non-GAAP gross profit | $ | 21,721 | $ | 25,595 | ||||
| Gross margin percentage | ||||||||
| Amortization of acquired intangible assets | ||||||||
| Depreciation and amortization | ||||||||
| Stock-based compensation expense | ||||||||
| Loss on disposal of property and equipment | ||||||||
| Cost of sales adjustment | (4.0)% | |||||||
| Non-GAAP gross margin percentage | ||||||||
| STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GAAP TO NON-GAAP OPERATING EXPENSES | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Operating expenses | $ | 52,711 | $ | 84,370 | ||||
| Restructuring and related charges | (1,552 | ) | (4,284 | ) | ||||
| Transaction and integration expenses | (1,124 | ) | (17,163 | ) | ||||
| Stock-based compensation expense | (8,514 | ) | (11,372 | ) | ||||
| Amortization of acquired intangible assets | (181 | ) | (150 | ) | ||||
| Depreciation and amortization | (2,537 | ) | (2,064 | ) | ||||
| Loss on disposal of property and equipment | (154 | ) | (14 | ) | ||||
| Non-GAAP operating expenses | $ | 38,649 | $ | 49,323 | ||||
| R&D operating expenses | $ | 11,328 | $ | 15,980 | ||||
| Stock-based compensation expense | (740 | ) | (1,328 | ) | ||||
| Depreciation and amortization | (590 | ) | (871 | ) | ||||
| Loss on disposal of property and equipment | (112 | ) | — | |||||
| Non-GAAP R&D operating expenses | $ | 9,886 | $ | 13,781 | ||||
| SG&A operating expenses | $ | 38,707 | $ | 46,943 | ||||
| Stock-based compensation expense | (7,774 | ) | (10,044 | ) | ||||
| Amortization of acquired intangible assets | (181 | ) | (150 | ) | ||||
| Depreciation and amortization | (1,947 | ) | (1,193 | ) | ||||
| Loss on disposal of property and equipment | (42 | ) | (14 | ) | ||||
| Non-GAAP SG&A operating expenses | $ | 28,763 | $ | 35,542 | ||||
| STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (In thousands) (Unaudited) | ||||||||
| ITEMIZED RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Net loss | $ | (26,033 | ) | $ | (32,157 | ) | ||
| Income tax (benefit) expense | (151 | ) | 128 | |||||
| Interest income | (2,916 | ) | (6,207 | ) | ||||
| Interest expense | 2 | 1,033 | ||||||
| Amortization of acquired intangible assets | 898 | 2,106 | ||||||
| Depreciation and amortization | 3,273 | 3,088 | ||||||
| Bargain purchase gain | — | (25,213 | ) | |||||
| Restructuring and related charges | 1,552 | 4,284 | ||||||
| Transaction and integration expenses | 1,124 | 17,163 | ||||||
| Stock-based compensation expense | 9,009 | 11,611 | ||||||
| Cost of sales adjustment | — | (1,812 | ) | |||||
| Loss on disposal of property and equipment | 185 | 14 | ||||||
| Other non-operating (income) expense | (3,871 | ) | 2,234 | |||||
| Adjusted EBITDA | $ | (16,928 | ) | $ | (23,728 | ) | ||
FAQ
What were Standard BioTools (LAB) key financial results for Q1 2025?
How much did Standard BioTools (LAB) reduce its operating expenses in Q1 2025?
What is Standard BioTools (LAB) revenue guidance for full-year 2025?
How did Standard BioTools (LAB) different revenue segments perform in Q1 2025?
What was Standard BioTools (LAB) cash position as of March 31, 2025?
